Guidance
Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.
These recommendations are in line with recommendation 1.1.10 in NICE’s antimicrobial prescribing guideline on C. difficile infection and NICE’s interventional procedures guidance on faecal microbiota transplant for recurrent C. difficile infection.
Implementation
NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice.
Is this guidance up to date?
Next review: 2025
Guidance development process
How we develop NICE medical technologies guidance
NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice.
If the case for adopting the technology is supported, the specific recommendations are not intended to limit use of other relevant technologies that may offer similar advantages. If the technology is recommended for use in research, the recommendations are not intended to preclude the use of the technology but to identify further evidence which, after evaluation, could support a recommendation for wider adoption.